While people with mCRPC harboring a ATM mutations have not consistently responded to PARPi in clinical trials in PCa, cell line models suggest that treating ATM altered tumors with both a PARP inhibitor and an ATR inhibitor may be more efficacious as compared with PARP inhibition alone [90]. The gene discussed is PARP1; the disease is posterior cortical atrophy.